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AbstrACt
Aims the EuroMyositis registry facilitates collaboration 
across the idiopathic inflammatory myopathy (IIM) 
research community. this inaugural report examines 
pooled registry data.
Methods Cross-sectional analysis of IIM cases from 11 
countries was performed. Associations between clinical 
subtypes, extramuscular involvement, environmental 
exposures and medications were investigated.
results of 3067 IIM cases, 69% were female. the 
most common IIM subtype was dermatomyositis (dM) 
(31%). Smoking was more frequent in connective tissue 
disease overlap cases (45%, or 1.44, 95% CI 1.09 to 
1.90, p=0.012). Smoking was associated with interstitial 
lung disease (ILd) (or 1.32, 95% CI 1.06 to 1.65, 
p=0.013), dysphagia (or 1.43, 95% CI 1.16 to 1.77, 
p=0.001), malignancy ever (or 1.78, 95% CI 1.36 to 
2.33, p<0.001) and cardiac involvement (or 2.40, 95% 
CI 1.60 to 3.60, p<0.001). dysphagia occurred in 39% 
and cardiac involvement in 9%; either occurrence was 
associated with higher Health Assessment Questionnaire 
(HAQ) scores (adjusted or 1.79, 95% CI 1.43 to 2.23, 
p<0.001). HAQ scores were also higher in inclusion 
body myositis cases (adjusted or 3.85, 95% CI 2.52 
to 5.90, p<0.001). Malignancy (ever) occurred in 13%, 
most commonly in dM (20%, or 2.06, 95% CI 1.65 to 
2.57, p<0.001). ILd occurred in 30%, most frequently 
in antisynthetase syndrome (71%, or 10.7, 95% CI 8.6 
to 13.4, p<0.001). rash characteristics differed between 
adult-onset and juvenile-onset dM cases (’V’ sign: 
56% dM vs 16% juvenile-dM, or 0.16, 95% CI 0.07 to 
0.36, p<0.001). Glucocorticoids were used in 98% of 
cases, methotrexate in 71% and azathioprine in 51%.
Conclusion this large multicentre cohort demonstrates 
the importance of extramuscular involvement in patients 
with IIM, its association with smoking and its influence 
on disease severity. our findings emphasise that IIM is a 
multisystem inflammatory disease and will help inform 
prognosis and clinical management of patients.
IntroduCtIon
The idiopathic inflammatory myopathies (IIM), 
or ‘myositis spectrum disorders’, are a rare and 
heterogeneous group of multisystem autoimmune 
diseases. IIM traditionally encompasses polymy-
ositis (PM), dermatomyositis (DM) and juvenile 
dermatomyositis (JDM). Inclusion body myositis 
(IBM) has become recognised as an entity distinct 
from PM, identified by a characteristic distribu-
tion of muscle weakness and treatment-resistant 
course. Additionally, skeletal muscle inflammation 
can occur in the context of other connective tissue 
diseases (CTDs), termed CTD-overlap myositis. 
Immune-mediated necrotising myopathy (IMNM) 
and the antisynthetase syndrome (ASS) are also 
now recognised as distinct entities under the IIM 
umbrella.1 The importance of serotype in predicting 
clinical features and prognosis is becoming increas-
ingly recognised.2 
Estimates of the prevalence of IIM vary widely 
from 0.55 to 17.50 per 1 00 000 people.3 The rarity 
and heterogeneity of IIM has hampered research 
efforts and impeded the delivery of large-scale 
interventional clinical trials.4 Consequently, the 
therapeutic evidence-base in IIM is remarkably 
limited.5 6 Recently, several IIM research databases 
and registries have been created to pool resources 
and expertise, facilitating completion of several 
international IIM research studies.7–11
We describe the data held within EuroMyositis, 
the largest IIM disease registry, highlighting the 
differing clinical characteristics of each IIM diag-
nostic subtype and analyse associations with extra-
muscular involvement, malignancy, environmental 
exposures and disease severity.
Methods
the euroMyositis registry
Several smaller registries were integrated in 2003 to 
produce the EuroMyositis Registry (https:// euromy-
ositis. eu/) (see online supplementary appendix A).
Anonymised downloads from those agreeing 
to participate (Belgium, China, Czech Republic, 
Hungary, Italy, Mexico, Norway, Sweden, Swit-
zerland, the UK and Vietnam) were obtained on 
15 August 2016, including 92% (3487/3790) of all 
cases in the Registry. During data processing, 420 
cases were excluded from further analysis; for 317 
cases, confirmation of diagnosis was not available, 
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for 55 cases, conflicting data entries were identified and the 
remaining 48 cases had rare IIM subtypes (see online supple-
mentary appendix B). A total of 3067 cases (81% of the whole 
Registry) were included in the final analysis.
Analysed sections of the Registry included demographics, clin-
ical features and environmental/lifestyle exposures, including 
smoking and toxins (asbestos, silica, fibreglass, solvents and coal 
dust). Where available (64%, 1951/3067), the autoantibody 
profile for each case was obtained to facilitate accurate diag-
nostic subtype classification. Specific analysis of the associations 
between serotype and phenotype will be the subject of a separate 
publication. Disease severity assessments made using the Inter-
national Myositis Assessment & Clinical Studies Group Core Set 
Measures ‘disease activity’ and ‘disease damage’ toolkits12 were 
obtained where available, as were records of any medications 
prescribed for IIM treatment. Longitudinal data were avail-
able for some cases (19%, 596/3067), although we limited this 
report to cross-sectional analysis using information from the last 
recorded patient visit.
definitions
Investigators at each site initially determined the diagnostic 
subtype for each case according to the criteria employed by the 
Registry (see online supplementary appendix B). In addition, 
rather than retain traditional subtype designation of cases as 
either PM, DM or JDM, and given the growing consensus that 
the different IIM subtypes, particularly ASS and IMNM have 
distinct clinical, pathological and serological characteristics,13–16 
we performed a process of retrospective subtype reclassification 
using the data available in the Registry at the time of study.
PM, DM and JDM cases met Bohan and Peter ‘definite’ or 
‘probable’ diagnostic criteria.17 18 The Registry specifies that 
these criteria should only be applied (and thus permit inclusion of 
the patient in the Registry as a PM, DM or JDM case), if known 
infectious, toxic, metabolic, dystrophic or endocrine myopa-
thies have been excluded by appropriate evaluations and that no 
exclusion criteria are met (see online supplementary appendix 
B). IBM cases met either the Medical Research Council, Griggs 
et al or European Neuromuscular Centre diagnostic criteria.19–21
Those with suspected PM, DM or JDM, who did not fulfil 
these criteria were classified as ‘unspecified myositis’ and 
excluded from further analysis, unless they met the criteria for 
ASS (in which case they were analysed within the ASS group, 
see below) or had myositis overlapping with a CTD (in which 
case they were analysed with the CTD-overlap myositis group). 
CTD-overlap myositis was defined as PM, DM, JDM or unspec-
ified myositis coexisting with a CTD that met relevant diagnostic 
criteria.22–26 This report uses the term JDM for current adults 
with juvenile-onset (<18 years) disease. Six cases of ‘juvenile 
PM’ were excluded from further analysis due to the rarity of this 
diagnostic entity and the difficulty in drawing conclusions from 
such a small sample.
For the purposes of this report, we pooled those with ASS 
(including where felt to be occurring in association with another 
IIM diagnostic subtype) into a single category by applying criteria 
proposed by Connors et al.27 This included retrospective reclas-
sification of those with PM, DM, JDM or CTD-overlap myositis 
cases as having ASS if they possessed an antisynthetase autoanti-
body (anti-Jo1, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS 
or anti-Zo autoantibodies), where results of these were available. 
These were combined with cases where the recruiting clinician 
deemed that criteria for ASS were met at the time of recruitment 
(see online supplementary appendix B). We also reclassified 
those with ‘unspecified myositis’ and amyopathic DM28 as ASS 
if they possessed an antisynthetase antibody and had coexisting 
interstitial lung disease (ILD), Raynaud’s phenomenon, arthritis 
or mechanics’ hands. Remaining cases with clinically amyopa-
thic DM were analysed as part of the DM group (n=38). We 
excluded a small number of cases where conflicting data were 
identified. This included 28 patients with PM, IMNM and IBM 
that had the presence of a DM-specific rash recorded and 27 
patients with DM where the presence of a DM-specific rash 
could not be confirmed.
The Registry categorises statin-related myotoxicity (SRM) 
cases using definitions suggested by Alfirevic et al (SRM1–6).29 
We reclassified as IMNM any case with statin-associated IMNM 
(SRM6) or SRM occurring in association with 3-hydroxy-3-meth-
ylglutaryl-coenzyme A reductase (anti-HMGCR) autoantibodies. 
Remaining cases with SRM1-5 were excluded from further anal-
ysis (n=16). We also reclassified as IMNM any case of PM that 
had anti-SRP or anti-HMGCR autoantibodies. All diagnostic 
subtype classifications were applied in a mutually exclusive 
manner (ie, cases could not be assigned to two IIM subtype 
groups). A summary of all diagnostic reclassifications is shown 
in online supplementary appendix B.
Malignancy is recorded in the EuroMyositis Registry regard-
less of the relationship to the diagnosis of IIM. We assigned cases 
a label of ‘cancer-associated myositis’ (CAM), where malignancy 
was diagnosed within 3 years of IIM diagnosis.30 31 Smoking 
was defined as having ever smoked at least one cigarette per 
day for more than 1 year. Cardiac involvement was defined as 
the occurrence of pericarditis, myocarditis, arrhythmia or sinus 
tachycardia occurring due to the IIM disease process. ILD was 
defined by chest X-ray or CT, and abnormal pulmonary function 
tests, and occurring as part of the IIM disease process. Disease 
onset was the date of onset of the first symptoms of IIM. Envi-
ronmental toxin exposure refers to prior exposure to any of 
asbestos, silica, fibreglass, solvents or coal dust. Further details of 
the definitions used by the EuroMyositis Registry are contained 
in online supplementary appendix A.
statistics
Downloaded data were imported into STATA for Windows 
V.13.0 (College Station, Texas, USA) for processing. Cross-sec-
tional descriptive statistical analysis was performed. For contin-
uous variables, normally distributed data were summarised by 
calculation of means and SD. Non-normally distributed data 
were summarised using medians and IQR. Associations were 
assessed using logistic regression and expressed as OR and 95% 
CI. This was performed unadjusted, except with regard to anal-
ysis of disease activity data from the last patient visit, which was 
adjusted for disease duration. Kaplan-Meier analysis and propor-
tional hazards regression was used to analyse differences in the 
interval between disease onset and diagnosis. In this case, the HR 
is presented to indicate the likelihood of a diagnosis being made 
over time. Where frequencies are presented, the denominator 
may vary between different variables because of missing data. 
No imputation was performed and only complete cases for each 
variable were analysed. A p value of <0.05 was considered as 
statistically significant.
results
Case characteristics
Data regarding 3067 cases from 11 countries were analysed. 
The most common diagnoses were DM (31%, 949/3067), 
PM (27%, 813/3067) and ASS (17%, 512/3067) (table 1). Of 
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those with CTD-overlap myositis, systemic sclerosis (SSc) was 
the most common coexisting CTD (39%, 141/358). Most cases 
were Caucasian (80%, 2155/2681), and 69% (2058/3002) 
were female. Those with IBM were more likely to be male than 
those with other diagnostic subtypes (61% (142/233) IBM vs 
29% (802/2769) for remainder, OR 3.83, 95% CI 2.91 to 5.04, 
p<0.001).
The mean age at IIM diagnosis was 51 years (SD 17) (table 1). 
IBM cases (mean age at diagnosis 65 years, SD 10) and IMNM 
cases (mean age at diagnosis 57 years, SD 15) were older at time 
of diagnosis when compared with the remainder of the adult-
onset myositis cohort (IBM: p<0.001; IMNM: p=0.003). The 
overall median interval between disease onset and IIM diag-
nosis was 8 months (IQR 3–22, n=1668). This was significantly 
longer for IBM cases (median 41 months (IQR 24–72), HR 0.38, 
95% CI 0.33 to 0.44, p<0.001) and significantly shorter for 
DM, ASS and IMNM cases (DM: median 5 months (IQR 2–11), 
HR 1.71, 95% CI 1.54 to 1.90, p<0.001; ASS: median 7 months 
(IQR 3–13), HR 1.28, 95% CI 1.13 to 1.44, p<0.001; IMNM: 
median 7 (IQR 4–12), HR 1.28, 95% CI 1.02 to 1.61, p=0.037) 
when compared with the remainder of the cohort.
Heliotrope rash and Gottron’s papules/sign were observed 
in similar proportions in those with DM and JDM. However, 
the shawl and ‘V’ signs were less common in those with JDM 
(shawl sign: 45% (234/522) of DM vs 15% (6/40) of JDM, OR 
0.22, 95% CI 0.09 to 0.53, p=0.001; ‘V’ sign: 56% (308/554) 
of DM vs 16% (7/43) of JDM, OR 0.16, 95% CI 0.07 to 0.36, 
p<0.001). Calcinosis occurred in 6% (78/1314) of cases overall 
but was more common in those with JDM (44% (23/52) of JDM 
vs 4% (55/1262), OR 17.4, 95% CI 9.45 to 32.04, p<0.001) 
and CTD-overlap myositis (10% (16/165) of CTD-overlap vs 
5% (62/1149), OR 1.88, 95% CI 1.06 to 3.35, p=0.031) when 
compared with the remainder of the cohort. Of the ASS cases, 
90% (439/487) had myopathic muscle weakness, 71% (357/502) 
table 1 Demographic and clinical information of cases in the EuroMyositis Registry
dermatomyositis Polymyositis
Antisynthetase 
syndrome
Connective tissue 
disease-overlap 
myositis
Inclusion body 
myositis
Immune- 
mediated 
necrotising 
myopathy
Juvenile 
dermato-
myositis
total
n (%)
Number of cases—n 
(% of total)
949 (31) 813 (27) 512 (17) 358 (12)* 240 (8) 105 (3) 90 (3) 3067 (100)
Gender—% male | % 
female (n=3002)
30 | 70 29 | 71 31 | 69 21 | 79 61 | 39 36 | 64 32 | 68 944 (32) male
2058 (69) female
Ethnicity—% per 
diagnosis (n=2681)
  Caucasian 75 74 86 86 96 93 76 2155 (80)
  Asian/Oriental 15 20 6 10 3 4 12 332 (12)
  Hispanic 7 4 1 1 0 2 9 98 (4)
  Black African 3 3 5 3 1 1 3 81 (3)
  Other 0 0 2 1 0 0 0 15 (1)
Mean age in years 
at disease onset (SD) 
(n=2427)
49 (15) 50 (15) 48 (15) 45 (15) 61 (10) 56 (15) 10 (5) 49 years (SD 16)
Mean age in years 
at diagnosis (SD) 
(n=2000)
51 (15) 52 (15) 49 (15) 48 (15) 65 (10) 57 (15) 10 (5) 51 years (SD 17)
Median interval in 
months between 
disease onset and 
diagnosis (IQR) 
(n=1668†)
5 (2–11) 8 (3–19) 7 (3–13) 11 (4–24) 41 (24–72) 7 (4–12) 8 (3–22) 8 months
(IQR 3–22)
Clinical features—% 
per diagnosis
Myopathic muscle 
weakness (n=2521)
92 98 90 94 92 94 91 2352 (93)
Rash‡ (n=1993) 100 0 44 32 0 0 100 1077 (54)
Raynaud’s phenomenon 
(n=1903)
25 28 51 60 8 20 18 643 (34)
Periungal erythema 
(n=1305)
52 6 32 33 2 15 37 434 (33)
Arthritis (n=2288) 20 20 50 42 8 10 23 632 (28)
Mechanics’ hands 
(n=1958)
22 8 38 16 1 4 7 363 (19)
Calcinosis (n=1314) 7 1 3 10 1 0 44 78 (6)
Ulceration (n=1152) 13 2 3 10 0 2 5 79 (7)
Disease onset is defined as the date of onset of the first symptoms of idiopathic inflammatory myopathy.
*Associated connective tissue diseases: systemic sclerosis (39%, 141/358), Sjögrens syndrome (15%, 54/358), mixed connective tissue disease (15%, 52/358), rheumatoid 
arthritis (9%, 32/358), systemic lupus erythematosus (9%, 32/358), other (13%, 47/358).
†Excludes 281 cases where diagnosis and onset are recorded with the same date.
‡Includes Gottron’s papules/sign heliotrope, rash, ‘V’ sign, shawl sign and erythroderma.
33Lilleker JB, et al. Ann Rheum Dis 2018;77:30–39. doi:10.1136/annrheumdis-2017-211868
Clinical and epidemiological research
ILD, 51% (198/385) Raynaud’s phenomenon, 50% (238/472) 
arthritis and 38% (146/380) mechanics’ hands.
environmental exposures
Overall, 37% (611/1646) of cases were smokers (table 2). 
Smoking was more common in CTD-overlap myositis cases 
compared with the remainder of the cohort (45% (103/231) 
vs 36% (508/1415), OR 1.44, 95% CI 1.08 to 1.90, p=0.012). 
Prior exposure to environmental toxins was observed more 
frequently in those with IBM (28% (21/75) vs 16% (136/855), 
OR 2.06, 95% CI 1.20 to 3.52, p=0.008). Environmental toxin 
exposure was also more common in smokers, compared with 
table 2 Environmental exposures, extramuscular complications and disease severity assessments of cases in the EuroMyositis Registry
dermatomyositis Polymyositis
Antisynthetase 
syndrome
Connective 
tissue disease-
overlap 
myositis
Inclusion body 
myositis
Immune- 
mediated 
necrotising 
myopathy
Juvenile 
dermatomyositis
total
n (%)
environmental 
exposures—% per 
diagnosis
Current or previous 
smoker (n=1646)
33 39 42 45 35 29 20 611(37)
Environmental toxin 
exposure (n=930)
16 17 21 15 28 4 0 157 (17)
extramuscular 
complications— % 
per diagnosis
Interstitial lung 
disease (n=2442)
21 17 71 32 3 10 6 720 (30)
Cardiac involvement 
(n=1715)
9 9 11 12 4 10 7 156 (9)
Malignancy ever 
(n=2788)
Of these—% with 
each type*:
20 8 12 13 16 7 0 374 (13)
  Breast 22 23 17 16 8 14 – 19%
  Bowel 8 7 12 14 21 0 – 10%
  Ovarian 13 2 2 3 0 0 – 7%
  Lung 10 7 14 9 0 0 – 9%
  Other 52 63 61 59 72 86 – 58%
‘Cancer -associated 
myositis’† (n=2701)
9 3 3 3 5 3 – 132 (5)
Dysphagia (n=1945) 43 35 26 53 50 36 16 767 (39)
disease severity 
assessments at 
last visit— median 
(IQr), n
Median (IQr), 
n
Duration of follow-up 
in years‡
2.6 (1.5–6.1), 186 2.8 (1.3–5.6), 
124
3.2 (1.8–6.5), 123 3.8 (2.1–6.6), 91 3.3 (1.5–5.9), 33 2.2 (0.7–5.6), 
23
1.3 (0.5–7.1), 16 3.0 (1.5–6.1), 
596
MMT-8 score (0–80) 75 (64–79), 156 72 (61–78), 89 75 (69–80), 93 71 (59–77), 55 63 (53–70), 21 69 (57–77), 21 78 (70–80), 7 73 (63–79), 442
Physician-completed 
global disease 
activity VAS (0–100)
10 (1–26), 258 10 (2–26), 156 9 (1–24), 163 8 (1–27), 107 14 (4–29), 39 16 (10–53), 36 10 (0–23), 13 10 (1–26), 772
Patient-completed 
global disease 
activity VAS (0–100)
30 (5–55), 203 45 (28–55), 103 40 (10–55), 123 47 (22–64), 83 44 (24–67), 32 42 (10–60), 30 3 (1–16), 13 40 (11–57), 587
HAQ-DI (0–3) 0.50 (0–1.25), 239 0.88 (0.25–
1.50), 132
0.63 (0–1.25), 142 0.88 (0.38–1.50), 
98
1.82 (1.38–2.50), 
38
0.56 (0.13–
2.13), 26
0 (0–0.13), 17 0.75 (0.13–
1.50), 692
Creatine kinase (as 
ratio of ULN)
0.44 (0.29–0.97), 63 1.12 (0.45–
3.20), 62
0.63 (0.35–2.06), 
40
0.66 (0.31–1.90), 
19
1.79 (1.17–2.02), 
5
1.28 (0.63–
2.79), 8
0.56 (0.39–1.85), 11 0.63 (0.37–
1.78), 208
Extramuscular 
disease activity VAS 
(0–100)
7 (0–22), 237 4 (0–15), 141 8 (0–18), 149 6 (0–16), 100 0 (0–15), 35 0 (0–15), 29 12 (0–27), 11 5 (0–18), 702
Myositis Damage 
Index global VAS 
(0–100)
16 (3–34), 146 20 (5–38), 84 19 (8–34), 85 26 (8–36), 58 47 (39–62), 22 14 (3–40), 18 29 (11–41), 8 20 (6–38), 421
*Multiple malignancies were recorded in some cases, therefore total may exceed 100%.
†Malignancy diagnosed within 3 years of the idiopathic inflammatory myopathy diagnosis.
‡For cases with >1 visit with any disease severity assessment recorded. Environmental toxin exposure includes exposure to asbestos, silica, fibreglass, solvents or coal dust.
HAQ-DI, Health Assessment Questionnaire-Disability Index; VAS, visual analogue scale; MMT-8, manual muscle test-8 score; ULN, upper limit of normal.
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those that had never smoked (26% (71/273) vs 13% (73/571), 
OR 2.40, 95% CI 1.66 to 3.46, p<0.001).
disease activity and disease damage assessments
At the last patient visit, lower manual muscle testing-8 (MMT-8) 
scores (adjusted OR 0.95, 95% CI 0.93 to 0.98, p<0.001) 
and higher Health Assessment Questionnaire-Disability Index 
(HAQ-DI) scores (adjusted OR 3.85, 95% CI 2.52 to 5.90, 
p<0.001) were observed in those with IBM compared with the 
remainder of the cohort (table 2). IBM cases also had a higher 
Myositis Damage Index (MDI) global VAS compared with the 
remainder of the cohort (median 47 (IQR 39–62) vs 19 (IQR 
5–36), adjusted OR 1.05, 95% CI 1.03 to 1.07, p<0.001).
Cases with ASS had a higher MMT-8 score at the last patient 
visit compared with the remainder of the cohort (adjusted 
OR 1.03, 95% CI 1.01 to 1.05, p=0.019). Cases with DM, 
JDM and ASS had lower HAQ-DI scores compared with the 
remainder of the cohort (DM: adjusted OR 0.74, 95% CI 0.60 
to 0.91, p=0.004. JDM: adjusted OR 0.09, 95% CI 0.02 to 
0.47, p=0.004. ASS: adjusted OR 0.72, 95% CI 0.57 to 0.93, 
p=0.011).
extramuscular involvement and malignancy
Interstitial lung disease
Overall, 30% (720/2442) of cases had ILD (table 2), observed 
most frequently in those with ASS (71% (357/502) vs 19% in 
remainder of cohort (363/1940), OR 10.7, 95% CI 8.6 to 13.4, 
p<0.001). ILD was least frequent in those with IBM (3%, 7/218) 
and JDM (6%, 4/72). In cases with ILD, current or previous 
smoking and prior exposure to environmental toxins were 
observed more frequently than in those without ILD (smoking: 
41% (191/462) vs 35% (387/1114), OR 1.32, 95% CI 1.06 to 
1.65, p=0.013; toxin exposure: 22% (57/256) vs 14% (93/651), 
OR 1.72, 95% CI 1.19 to 2.48, p=0.004) (table 3). At their last 
visit, cases with ILD had a higher extramuscular disease activity 
VAS (median 10 (IQR 2–22) vs 3 (IQR 0–15), adjusted OR 1.02, 
95% CI 1.01 to 1.03, p=0.001) and MDI global VAS (median 25 
(IQR 13–40) vs 14 (IQR 4–37), adjusted OR 1.01, 95% CI 1.00 
to 1.02, p=0.005) (table 3).
Cardiac involvement
Nine per cent (156/1715) of cases had cardiac involvement 
(table 2). This was most frequently observed in those with 
CTD-overlap myositis (12%, 27/230). Overall, those with SSc 
were more likely to have cardiac involvement compared with 
those without SSc (18% (13/74) vs 9% (143/1641), OR 2.23, 
95% CI 1.20 to 4.16, p=0.011). Cardiac involvement was less 
frequent in those with IBM compared with the remainder of the 
cohort (4% (8/185) vs 10% (148/1530), OR 0.42, 95% CI 0.20 
to 0.87, p=0.020). Smoking was significantly more frequent in 
those with cardiac involvement compared with those without 
(55% (56/102) vs 34% (426/1265), OR 2.40, 95% CI 1.60 to 
3.60, p<0.001) (table 3). Cardiac involvement was also asso-
ciated with exposure to environmental toxins (27% (18/68) vs 
14% (97/702), OR 2.25, 95% CI 1.26 to 4.01, p=0.006).
At the last patient visit, the presence of cardiac involvement 
was associated with a higher patient-completed global disease 
activity VAS (median 50 (IQR 31–66) vs 41 (12-59), adjusted 
OR 1.02, 95% CI 1.00 to 1.03, p=0.007), HAQ-DI (median 
1.00 (IQR 0.38–1.63) vs 0.67 (IQR 0.13–1.38), adjusted OR 
1.52, 95% CI 1.10 to 2.12, p=0.012), extramuscular disease 
activity VAS (median 12 (3-25) vs 7 (0–19), adjusted OR 1.02, 
95% CI 1.00 to 1.03, p=0.017) and MDI global VAS (median 31 
(IQR 12–48) vs 20 (IQR 5–38), adjusted OR 1.01, 95% CI 1.00 
to 1.03, p=0.047) (table 3).
Gastrointestinal involvement
Dysphagia was observed in 39% (767/1945) of cases and was 
more common in those with CTD-overlap myositis (53% 
(137/258), OR 1.90, 95% CI 1.46 to 2.47, p<0.001) (table 2). 
The presence of dysphagia was more frequent in those with SSc 
(67% (63/94), OR 3.31, 95% CI 2.13 to 5.14, p<0.001). The 
rate of dysphagia was also higher in those with IBM compared 
with the remainder of the cohort (50% (111/224), OR 1.60, 
95% CI 1.21 to 2.11, p=0.001).
Smoking was more frequent in those with dysphagia (42% 
(247/584) vs 34% in those without dysphagia (322/951), OR 
1.43, 95% CI 1.16 to 1.77, p=0.001) (table 3). At the last patient 
visit, dysphagia was associated with a higher patient-completed 
global disease activity VAS (median 46 (IQR 17–65) vs 37 (IQR 
10–53), adjusted OR 1.01, 95% CI 1.00 to 1.02, p=0.007), 
HAQ-DI (median 1.0 (IQR 0.25–1.63) vs 0.63 (IQR 0.13–1.13), 
adjusted OR 1.60, 95% CI 1.30 to 1.96, p<0.001), extramus-
cular global VAS (median 7 (IQR 0–21) vs 5 (IQR 0–16), adjusted 
OR 1.02, 95% CI 1.01 to 1.03, p=0.003) and MDI global VAS 
(median 25 (IQR 10–43) vs 17 (IQR 3–32), adjusted OR 1.02, 
95% CI 1.01 to 1.03, p=0.001). The MMT-8 score was lower 
in those with dysphagia (median 71 (IQR 59–78) vs 73 (IQR 
64–78), adjusted OR 0.98, 95% CI 0.96 to 0.99, p=0.044).
Malignancy
Malignancy occurred in 13% (374/2788) of cases (table 2). 
Breast cancer was the most frequently observed cancer subtype 
(affecting 19% of those with cancer (70/374)). DM cases had 
a higher frequency of malignancy (20% (166/841) vs 11% 
(208/1947) in non-DM cases, OR 2.06, 95% CI 1.65 to 2.57, 
p<0.001). No malignancy was recorded in cases with JDM. Of 
those with cancer, CAM was defined in 46% (132/287; onset 
dates missing for remaining 87). CAM was more common in 
those with DM compared with the remainder of the cohort 
(9% (72/795) vs 3% (60/1906), OR 3.06, 95% CI 2.01 to 4.36, 
p<0.001). In those with CAM, the median interval between IIM 
diagnosis and cancer diagnosis was 1 month (ie, cancer onset 
1 month after IIM diagnosis, IQR −3 to +12 months) (figure 1).
Smoking was more frequent in those with malignancy (51% 
(133/263) vs 37% (472/1294), OR 1.78, 95% CI 1.36 to 2.33, 
p<0.001) (table 3). Those with malignancy were older at the 
time of IIM disease onset, compared with those without malig-
nancy (57 (SD 14) vs 48 (SD 16) years, OR 1.05, 95% CI 1.04 
to 1.05, p<0.001). The presence of malignancy was associated 
with a higher patient-completed global disease activity VAS 
(median 47 (IQR 24–64) vs 38 (IQR 10–55), adjusted OR 1.01, 
95% CI 1.00 to 1.02, p=0.009), HAQ-DI (median 1.13 (IQR 
0.63–1.63) vs 0.63 (IQR 0.13–1.38), adjusted OR 1.60, 95% CI 
1.26 to 2.04, p<0.001) and MDI global VAS (median 37 (IQR 
22–53) vs 17 (IQR 5–35), adjusted OR 1.03, 95% CI 1.02 to 
1.05, p<0.001) (table 3).
Medication
A total of 2613 instances of usage of medications to treat IIM 
were recorded in 1023 cases (table 4). Oral glucocorticoid usage 
was recorded in 98% (969/993) of cases. Higher proportions of 
intravenous immunoglobulin usage were evident for cases with 
JDM (25%, 12/49), IMNM (18%, 9/50) and IBM (17%, 8/47). 
Cases with ASS had the highest proportions with recorded usage 
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of both cyclophosphamide (39%, 44/114) and rituximab (14%, 
26/184).
When considering all forms of IIM, the preferred steroid 
sparing agents were methotrexate (71%, 500/704) and azathio-
prine (51%, 311/615). In those with ASS, usage rates of azathi-
oprine and methotrexate were similar (60% (77/128) and 60% 
(76/127), respectively). A high proportion of IBM cases had 
medication usage recorded in the ‘other biologic’ category (48%, 
14/29) relating to participation of Swedish patients with IBM in 
a clinical trial of anakinra.32
dIsCussIon
Using the large EuroMyositis Registry dataset, we have identified 
several important new associations, including the strong influ-
ence of extramuscular involvement (malignancy, cardiac involve-
ment and dysphagia) on disease severity. This was demonstrated 
by higher disease activity and damage scores, including worse 
functional performance according to the HAQ-DI. We found 
that smoking and environmental toxin exposure was associated 
with the occurrence of extramuscular involvement (ILD, cardiac 
involvement, malignancy and dysphagia), although this observa-
tion may relate more to direct toxic effects rather than be related 
to the IIM disease process itself.
We have also used data from the Registry to confirm several 
previously described observations. This includes the link between 
malignancy and DM, the different demographic characteristics 
of those with IBM compared with other IIM diagnostic subtypes 
and the differing skin disease characteristics of DM and JDM. 
We also found that cases with CTD-overlap disease, especially 
those with SSc, were at increased risk of cardiac involvement and 
dysphagia. We have demonstrated a similar frequency of ILD27 
and cardiac involvement33 in IIM as described in other sources 
in the literature. The frequency of malignancy we identified was 
towards the lower range of that reported.1
Figure 1 Onset of malignancy in relation to date of diagnosis 
of idiopathic inflammatory myopathy (IIM) for cases with cancer-
associated myositis. Month 0 indicates date of IIM diagnosis.
table 4 Medications used to treat idiopathic inflammatory myopathy in the EuroMyositis Registry
% within each diagnostic subtype 
with recorded use of each 
medication
dermatomyositis
(n=353)
Polymyositis
(n=206)
Antisynthetase 
syndrome
 (n=184)
Connective 
tissue 
disease-
overlap 
myositis
(n=134)
Inclusion 
body 
myositis
 (n=47)
Immune- 
mediated 
necrotising 
myositis
(n=50)
Juvenile 
dermatomyositis
(n=49)
overall total
n (% per 
medication)*
(2613 
medications 
in 1023 cases)
Glucocorticoids 98 100 98 96 89 98 96 969/993 (98)
Disease modifying antirheumatic drugs
Methotrexate 69 76 60 72 82 82 74 500/704 (71)
Azathioprine 44 52 60 51 35 59 57 311/615 (51)
Ciclosporin 31 27 31 23 4 28 40 152/545 (28)
Antimalarials 37 11 16 29 7 0 48 131/533 (25)
Mycophenolate 17 20 31 29 24 13 33 119/511 (23)
Tacrolimus 1 5 2 0 0 0 0 9/487 (2)
Leflunomide 0 3 3 4 0 6 6 11/489 (2)
Biological therapies
Rituximab 6 4 14 7 2 12 0 72/1025 (7)
Other biologic† 7 4 11 20 48 19 22 62/493 (13)
Immunomodulatory therapies
IVIg 11 13 7 7 17 18 25 118/1025 (12)
Plasma exchange 2 2 0 0 0 0 0 5/490 (1)
Other
Cyclophosphamide 15 14 39 18 4 17 6 101/520 (19)
Other (not specified) 5 3 8 10 14 0 11 34/501 (7)
Topical therapies
Topical glucocorticoids 7 2 2 1 4 0 6 18/489 (4)
Topical tacrolimus 0 0 0 1 0 0 0 1/485 (0)
Median number of recorded 
medications per case (IQR)
2 (1–3) 2 (1–3) 3 (2–4) 2 (2–3) 2 (2–3) 2 (1–3) 2 (1–3) two 
medications 
(IQR 1–3)
*Some cases have received mediation from multiple categories.
†Includes antitumour necrosis factors, anakinra and abatacept.
IMNM, immune-mediated necrotising myopathy; IVIg, intravenous immunoglobulin.
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The literature described complex associations between envi-
ronmental exposures and IIM. Smoking has been shown to 
interact with serotype (particularly anti-Jo1 autoantibody 
status) and genotype in IIM, and this may explain some of our 
findings.34 Additionally, several other environmental factors 
have been investigated, particularly ultraviolet light exposure, 
seasonal birth patterns and prior infections.35–37 Thus, while our 
observational data cannot imply a causative role for smoking 
or environmental toxin exposure in the development of extra-
muscular manifestations of IIM, it is possible that these environ-
mental factors could be of pathogenic relevance.
Disease registries are increasingly facilitating large-scale obser-
vational studies in IIM. In the USA, the MYOVISION registry 
has recently reported on factors associated with a reduced 
health-related quality of life in IIM.38 Factors identified included 
a diagnosis of IBM and the presence of ILD. We demonstrated a 
significantly higher HAQ-DI score in those with IBM compared 
with those with other IIM diagnostic subtypes. However, we did 
not demonstrate similar findings with regard to the presence of 
ILD. This may be explained by the fact that our analysis was 
restricted to understanding differences between IIM subtypes, 
whereas the MYOVISION authors compared data for IIM cases 
against normative data from the general population and from 
rheumatoid arthritis cases.
Our analysis has several limitations, many of which are 
inherent to analysis of disease registries. We did not perform 
any data validation, including verification of diagnosis. Differing 
local practices, for example, local methods of detecting cardiac 
involvement or malignancy, may have influenced the way data 
were recorded at individual sites and the definition used in the 
registry for some features (eg, ILD) may not include use of gold 
standard diagnostic techniques. Most had only cross-sectional 
data recorded, meaning that the incidence of some clinical 
features might be underestimated. In other cases, reporting bias 
may mean that some reported frequencies are overestimates. 
Usage rates of certain sections of the Registry also varied between 
centres, making analysis difficult in some cases. Additionally, in 
some cases it is possible that the associations demonstrated might 
be influenced by confounders that we have not accounted for.
Data now comprising the Registry were first recorded as 
early as 1999 in some cases. At that time, IMNM had not been 
recognised as a specific IIM subtype, there were no available clas-
sification criteria for ASS and several antisynthetase antibodies 
were yet to be discovered. Despite our attempts to minimise 
inclusion of misdiagnosed cases, there remains the possibility 
that some cases, particularly those with PM, could have been 
misdiagnosed. We also highlight the fact that several alterna-
tive proposed diagnostic and classification criteria for IIM are 
available, use of which may have influenced the results. The 
complexity of IIM and the lack of consensus diagnostic criteria 
or definitions of each subtype remain a significant problem for 
patients, clinicians and researchers alike. Such issues are likely to 
improve after ratification of the forthcoming European League 
Against Rheumatism/American College of Rheumatology IIM 
classification criteria.39
Further recruitment into the EuroMyositis Registry will 
increase our power to detect rarer associations and further eluci-
date rarer disease subtypes such as juvenile-PM. The steering 
committee welcomes applications for implementation in addi-
tional paediatric and adult centres (https:// euromyositis. eu).
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